Herpes Zoster News and Research

RSS
Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
Herpes zoster vaccine reduces risk of developing shingles by 55%

Herpes zoster vaccine reduces risk of developing shingles by 55%

Less than 7% of U.S. seniors get shingles vaccination

Less than 7% of U.S. seniors get shingles vaccination

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Anti-TNF therapy increases risk of varicella zoster virus infections

Anti-TNF therapy increases risk of varicella zoster virus infections

Aestus receives $244,000 grant from QTDP program

Aestus receives $244,000 grant from QTDP program

Merck reports $342 million net income for 2010 third quarter

Merck reports $342 million net income for 2010 third quarter

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Many adults skip vaccines because of costs

Many adults skip vaccines because of costs

PLX-PAD therapy improves quality of life in CLI patients

PLX-PAD therapy improves quality of life in CLI patients

DARA BioSciences presents KRN5500 study results at World Congress on Pain

DARA BioSciences presents KRN5500 study results at World Congress on Pain

Study: No association between first-trimester exposure to antiherpetic antiviral drugs and major birth defects

Study: No association between first-trimester exposure to antiherpetic antiviral drugs and major birth defects

Inhibitex reports net loss of $5.6 million for second-quarter 2010

Inhibitex reports net loss of $5.6 million for second-quarter 2010

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Merck reports strong bottom-line performance in second quarter

Merck reports strong bottom-line performance in second quarter